EFficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: A systematic review and network meta-analysis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Régnier, Stephane ^a   Malcolm, William ^b   Allen, Felicity ^b   Wright, Jonathan ^c   Bezlyak, Vladimir ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharmaceuticals UK Ltd   (United Kingdom)

^c Numerus Statistics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ARTICLE; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; META ANALYSIS; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; BAYES THEOREM; COMPLICATION; DIABETIC RETINOPATHY; DRUG EFFECTS; MACULAR EDEMA; PATHOLOGY; PROCEDURES; RETINA; RISK; VISION DISORDERS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BAYES THEOREM; DIABETIC RETINOPATHY; HUMANS; LASER COAGULATION; MACULAR EDEMA; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY;

EID: 84904353200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102309     Document Type: Article

References (73)

1. Boscia F (2010) Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs 70: 2171-2200.
2. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376: 124-136.
3. Ciulla TA, Amador AG, Zinman B (2003) Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26: 2653-2664. (Pubitemid 37055447)
4. Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M (2009) Diabetic retinopathy and health-related quality of life. Graefes Arch Clin Exp Ophthalmol 247: 267-272.
5. Lamoureux EL, Tai ES, Thumboo J, Kawasaki R, Saw SM, et al. (2010) Impact of diabetic retinopathy on vision-specific function. Ophthalmology 117: 757-765.
6. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A (2008) The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes 6: 95.
7. Delcourt C, Sivaprasad S, Bandello F, Pareja A, Klausmann G, et al. (Submitted) Prevalence of diabetic macular edema (DME) in Europe: the Pan European Prevalence Assessment of DME with Visual Impairment (PREVAIL) study.
8. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
9. The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines, December 2012. Available: http://www.rcophth.ac.uk/page.asp?section= 451§ionTitle= Clinical+Guidelines Accessed 17 January 2013.
10. American Academy of Ophthalmology Retina Panel (2008) Preferred Practice Pattern Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology.
11. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, et al. (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127: 245-251.
12. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. ETDRS Report number 1. Arch Ophthalmol 103: 1796-1806.
13. Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 94: 761-774.
14. Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98: 766-785.
15. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, et al. (2012) New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 26(4):: 485-493.
16. Lucentis (ranibizumab) Prescribing information. Updated 2012. Available: http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf Accessed 19 Sept 2012.
17. Lucentis (ranibizumab) Summary of product characteristics. Updated 20/7/12 Available: http://www.medicines.org.uk/emc/medicine/19409#INDICATIONS Accessed 19/09/2012.
18. Regeneron EYLEA (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema. Released November 7, 2013. Available: http://investor.regeneron.com/releasedetail.cfm?ReleaseID= 805219.
19. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS (2011) A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118: 1107-1118.
20. Loftus JV, Sultan MB, Pleil AM (2011) Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci 52: 7498-7505.
21. Cunningham ET, Jr., Adamis AP, Altaweel M, Aiello LP, Bressler NM, et al. (2005) A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757.
22. National Institute for Health and Care Excellence. Macular oedema (diabetic) - pegaptanib sodium [ID452]. Page last updated: 11 December 2013. Available at: http://guidance.nice.org.uk/TAG/280.
23. Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237). Issued April 2013. Available: http://www.nice.org.uk/nicemedia/live/14082/62873/62873.pdf.
24. Adcortyl SmPC. Available at: https://www.medicines.org.uk/emc/medicine/ 6392/SPC/Adcortyl+Intra-Articular+Intradermal+Injection+10mg+ml/. Accessed 12 February 2014.
25. National Institute for Health and Care Excellence.Single Technology Appraisal. Ranibizumab for the treatment of diabetic macular oedema. Final scope. As amendedOctober 2010. Available: http://www.nice.org.uk/nicemedia/live/ 13125/51140/51140.pdf.
26. ILUVIEN SPC. Available: http://www.mhra.gov.uk/Safetyinformation/ Medicinesinformation/SPCandPILs/?subsName=FLUOCINOLONE%20ACETONIDE&pageID= SecondLevel Accessed 07 January 2013.=
27. Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, et al. (2014) Pharmacological approach to diabetic macular edema. Ophthalmic Res 51: 88-95.
28. Jain A, Varshney N, Smith C (2013) The evolving treatment options for diabetic macular edema. Int J Inflam 2013: e689276.
29. Ford JA, Elders A, Shyangdan D, Royle P, Waugh N (2012) The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ 345: e5182.
30. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, et al. (2013) Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ open 3: e002269.
31. Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA (2011) Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta ophthalmologica 89: 709-717.
32. Zechmeister-Koss I, Huic M (2012) Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br J Ophthalmol 96: 167-178.
33. Ollendorf DA, Colby JA, Pearson SD (2013) Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Asses 29: 392-401.
34. Frampton JE (2012) Ranibizumab: in diabetic macular oedema. Drugs 72: 509-523.
35. Wang H, Sun X, Liu K, Xu X (2012) Intravitreal ranibizumab (Lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res 37: 661-670.
36. Virgili G, Parravano M, Menchini F, Brunetti M (2012) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 12: CD007419.
37. Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331: 897-900. (Pubitemid 41502718)
38. Jansen JP, Naci H (2013) Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 11: 159.
39. Ahmadian L, Massof R (2008) Impact of general health status on validity of visual impairment measurement. Ophthalmic Epidemiol 15: 345-355.
40. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J (2009) Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 127: 13-21.
41. Csaky KG, Richman EA, Ferris FL, 3rd (2008) Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 49: 479-489.
42. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, et al. (2001) Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119: 1050-1058. (Pubitemid 32652197)
43. Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, et al. (2002) Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review. Pharmacoeconomics 20: 791-812. (Pubitemid 35216491)
44. The Scottish Intercollegiate Guidelines Network (SIGN). Methodological Guidelines. Accessed February 2014. Available: http://www.sign.ac.uk/ methodology/index.html.
45. The National Institute for Health and Care Excellence (2012) The Guidelines Manual 2012. Available: http://www.nice.org.uk/aboutnice/howwework/ developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/ clinical-guideline-development-methods.jsp.
46. Brooks S, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7: 434-455. (Pubitemid 128635035)
47. Gelman A, Rubin D (1992) Inference from iterative simulation using multiple sequences. Statistical Science 7: 457-511.
48. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, et al. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
49. Welton N, Sutton A, Cooper N, Abrams K, Ades A (2012) Evidence synthesis for decision making in healthcare (statistics in practice). John Wiley & Sons Ltd, Chichester, United Kingdom
50. Dias S, Sutton AJ, Ades AE, Welton NJ (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33: 607-617.
51. Poku E, Brazier J, Carlton J, Ferreira A (2013) Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review. BMC Ophthalmol 13: 74.
52. Diabetic Retinopathy Clinical Research Network (2013) Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 131: 283-293.
53. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, et al. (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120: 2013-2022.
54. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, et al. (2013) Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 131: 139-145.
55. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, et al. (2012) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119: 2312-2318.
56. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS (2012) Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 130: 1145-1152.
57. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, et al. (2012) Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 53: 7666-7674.
58. Yilmaz MB, Teke MY, Saritepe S, Kara C, Taşkintuna I, et al. (2012) Intravitreal bevacizumab for refractory diabetic macular edema. Retina-vitreus 20: 265-272.
59. RaScaL: Ranibizumab and PRP in Patients With CSDME and Peripheral Nonperfusion (NCT00815360). Available: http://clinicaltrials.gov/ct2/show/ NCT00815360?term=NCT00815360&rank=1.
60. RED-ES: Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT00901186). Available: http://clinicaltrials.gov/ct2/show/ NCT00901186?term=NCT00901186&rank=1.
61. RELIGHT: Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment (NCT01257815). Available: http://clinicaltrials.gov/ct2/show/NCT01257815?term=NCT01257815&rank=1.
62. RESPOND: Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) (NCT01135914). Available: http://clinicaltrials.gov/ct2/show/NCT01135914?term= NCT01135914&rank=1.
63. OPTIMAL: Ranibizumab "Treat and Extend" in Diabetic Macular Edma (NCT01297569. Available: http://clinicaltrials.gov/ct2/show/NCT01297569? term=NCT01297569&rank=1.
64. VIVID: VEGF Trap-Eye in Vision Impairment Due to DME (NCT01331681). Available: http://clinicaltrials.gov/ct2/show/NCT01331681?term= NCT01331681&rank=1.
65. VISTA: Study of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (NCT01363440). Available: http://clinicaltrials.gov/ ct2/show/NCT01363440?term=NCT01363440&rank=1.
66. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, et al. (2012) One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119: 1658-1665.
67. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077 e1035.
68. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, et al. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399-2405.
69. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, et al. (2009) Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116: 2175-2181 e2171.
70. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Available: http://www.prisma-statement.org/.
71. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group (2014) The Neovascular Age-Related Macular Degeneration Database: Multicenter study of 92 976 ranibizumab injections: Report 1: visual acuity. Ophthalmology.
72. Regeneron (2013) IR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema (28 September 2013). Available at:http://files. shareholder.com/downloads/REGN/2709632625x0x693788/9a16d654-c5c7-44ed-b182- d752da5dab5c/VIVID%20VISTA%20FINAL%20Investor-Handouts-27Sept2013.pdf.
73. RESPOND: Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME). Novartis data on file to be submitted for publication.